In vivo apoptosis imaging agents and strategies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 1018-1023

  Zhao, Ming ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Apoptosis; Imaging; Probe

Indexed keywords

BINDING PROTEIN; BIOLOGICAL MARKER; CASPASE; DURAMYCIN; LANTHIOPEPTIN; LIPOCORTIN 5; SYNAPTOTAGMIN I; TECHNETIUM 99M;

APOPTOSIS; BINDING SITE; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOLECULAR WEIGHT; NON INVASIVE MEASUREMENT; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW;

ANNEXIN A5; APOPTOSIS; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 73449124065     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009789377691     Document Type: Review

References (101)

1. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 1972, 26, 239.
2. Kerr, J.F. History of the events leading to the formulation of the apoptosis concept. Toxicology, 2002, 181-182, 471.
3. Selivanova, G. p53: fighting cancer. Curre. Cancer Drug Targets, 2004, 4, 385.
4. Huang, P.; Heimbrook, D.C. Oncogene products as therapeutic targets for cancer. Curr. Opin. Oncol., 1997, 9, 94.
5. Gourley, M.; Williamson, J.S. Angiogenesis: new targets for the development of anticancer chemotherapies. Curr. Pharm. Des., 2000, 6, 417.
6. Song, Z.; Steller, H. Trends. Death by design: mechanism and control of apoptosis. Cell Biol., 1999, 9, M49.
7. Wyllie, A.H. Apoptosis: an overview. Br. Med. Bull., 1997, 53, 451.
8. Grutter, M.G. Caspases: key players in programmed cell death. Curr. Opin. Struct. Biol., 2000, 10, 649.
9. Green, D.R. Apoptotic pathways: the roads to ruin. Cell, 1998, 94, 695.
10. Thornberry, N.A.; Lazebnik, Y. Caspases: enemies within. Science, 1998, 281, 1312.
11. Fadok, V.A.; Voelker, D.R.; Campbell, P.A.; Cohen, J.J.; Bratton, D.L.; Henson, P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol., 1992, 148, 2207.
12. Emoto, K.; Toyama-Sorimachi, N.; Karasuyama, H.; Inoue, K.; Umeda, M. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp. Cell Res., 1997, 232, 430.
13. Williamson, P.; Schlegel, R.A. Transbilayer phospholipid movement and the clearance of apoptotic cells. Biochim. Biophys. Acta., 2002, 1585, 53.
14. Sahu, S.K.; Gummadi, S.N.; Manoj, N.; Aradhyam, G.K. Phospholipid scramblases: an overview. Arch. Biochem. Biophys., 2007, 462, 103.
15. Bevers, E.M.; Comfurius, P.; Zwaal, R.F. Regulatory mechanisms in maintenance and modulation of transmembrane lipid asymmetry: pathophysiological implications. Lupus, 1996, 5, 480.
16. Naito M.; Nagashima, K.; Mashima, T.; Tsuruo, T. Phosphatidylserine externalization is a downstream event of interleukin-1 beta-converting enzyme family protease activation during apoptosis. Blood, 1997, 89, 2060.
17. Dasgupta, S.K,. Guchhait, P.; Thiagarajan, P. Lactadherin binding and phosphatidylserine expression on cell surface-comparison with annexin A5. Transl. Res., 2006, 148, 19.
18. Tait, J.F.; Smith, C.; Wood, B.L. Measurement of phosphatidylserine exposure in leukocytes and platelets by whole-blood flow cytometry with annexin V. Blood Cells Mol. Dis., 1999, 25, 271.
19. Bewley, M.C.; Boustead, C.M.; Walker, J.H.; Waller, D.A.; Huber, R. Structure of chicken annexin V at 2.25-A resolution. Biochemistry, 1993, 32, 3923.
20. Sopkova, J.; Renouard, M.; Lewit-Bentley, A. J. The crystal structure of a new high-calcium form of annexin V. Mol. Biol., 1993, 234, 816.
21. Liemann, S.; Benz, J.; Burger, A.; Voges, D.; Hofmann, A.; Huber, R.; Göttig, P. Structural and functional characterisation of the voltage sensor in the ion channel human annexin V. J. Mol. Biol., 1996, 258, 555.
22. Blankenberg, F.G.; Katsikis, P.D.; Tait, J.F.; Davis, R.E.; Naumovski, L.; Ohtsuki, K.; Kopiwoda, S.; Abrams, M.J.; Darkes, M,; Robbins, R.C.; Maecker, H,T.; Strauss, H.W. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Natl. Acad. Sci. USA, 1998, 95, 6349.
23. Narula, J.; Acio, E.R.; Narula, N.; Samuels, L.E.; Fyfe, B,; Wood, D.; Fitzpatrick, J.M.; Raghunath, P.N.; Tomaszewski, J.E.; Kelly, C.; Steinmetz, N.; Green, A.; Tait, J.F.; Leppo, J.; Blankenberg, F.G.; Jain, D.; Strauss, H.W. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat. Med., 2001, 7, 1347.
24. Belhocine, T.; Steinmetz, N.; Hustinx, R.; Bartsch, P.; Jerusalem, G.; Seidel, L.; Rigo, P.; Green, A. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res., 2002, 8, 2766.
25. Thimister, P.W,; Hofstra, L.; Liem, I.H.; Boersma, H.H.; Kemerink, G.; Reutelingsperger, C.P.; Heidendal, G.A. In vivo detection of cell death in the area at risk in acute myocardial infarction. J. Nucl. Med., 2003, 44, 391.
26. Rottey. S.; Slegers, G.; Van Belle, S.; Goethals, I.; Van de Wiele, C. Sequential 99mTc-hydrazinonicotinamide-annexin V imaging for predicting response to chemotherapy. J. Nucl. Med., 2006, 47, 1813.
27. Haas, R.L.; de Jong, D.; Valdés Olmos, R.A.; Hoefnagel, C.A.; van den Heuvel, I.; Zerp, S.F.; Bartelink, H.; Verheij, M. Int. J. Radiat. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Oncol. Biol. Phys., 2004, 59, 782.
28. Sosnovik, D.E.; Schellenberger, E.A.; Nahrendorf, M.; Novikov, M.S.; Matsui, T.; Dai, G.; Reynolds, F.; Grazette, L.; Rosenzweig, A.; Weissleder, R.; Josephson, L. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med., 2005, 54, 718.
29. van Tilborg, G.A.; Mulder, W.J.; Chin, P.T.; Storm, G.; Reutelingsperger, C.P.; Nicolay, K.; Strijkers, G.J. Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multi-modal detection of apoptotic cells. Bioconjug. Chem., 2006, 17, 865.
30. Rongen, G.A.; Oyen, W.J.; Ramakers, B.P.; Riksen, N.P.; Boerman, O.C.; Steinmetz, N.; Smits, P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation, 2005, 111, 173.
31. Ntziachristos, V.; Schellenberger, E.A.; Ripoll, J.; Yessayan, D.; Graves, E.; Bogdanov, A. Jr.; Josephson, L.; Weissleder, R. Proc. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Natl. Acad. Sci. USA, 2004, 101, 12294.
32. Kiestelaer, B..L.J.H.; Reutelingsperger, C.P.M.; Heidendal. G.A.K.; Daemen, M.J.A.P.; Mess, W.H.; Hofstra, L. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N. Engl. J. Med., 2004, 350, 1472.
33. Johnson, L.L.; Schofield, L.; Donahay, T.; Narula, N.; Narula, J. 99mTc-annexin V imaging for in vivo detection of atherosclerotic lesions in porcine coronary arteries. J. Nucl. Med., 2005, 46, 1186.
34. Strauss, H.W.; Mari, C.; Patt, B.E.; Ghazarossian, V. Intravascular radiation detectors for the detection of vulnerable atheroma. J. Am. Coll. Cardiol., 2006, 47, C97.
35. Kemerink, G.J.; Liu, X.; Kieffer, D.; Ceyssens, S.; Mortelmans, L.; Verbruggen, A.M.; Steinmetz, N.D.; Vanderheyden, J.L.; Green, A.M.; Verbeke, K. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J. Nucl. Med., 2003, 44, 947.
36. Boersma, H.H,; Liem, I.H.; Kemerink, G.J.; Thimister, P.W.; Hofstra, L.; Stolk, L.M.; van Heerde, W.L.; Pakbiers, M.T.; Janssen, D.; Beysens, A.J.; Reutelingsperger, C.P.; Heidendal, G.A. Comparison between human pharmacokinetics and imaging properties of two conjugation methods for 99mTc-annexin A5. Br. J. Radiol., 2003, 76, 553.
37. Vanderheyden, J.L.; Liu, G.; He, J.; Patel, B.; Tait, J.F.; Hnatowich, D.J. Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice. Nucl. Med. Biol., 2006, 33, 135.
38. Tait, J.F.; Brown, D.S.; Gibson, D.F.; Blankenberg, F.G.; Strauss, H.W. Development and characterization of annexin V mutants with endogenous chelation sites for 99mTc. Bioconjug. Chem., 2000, 11, 918.
39. Tait, J.F.; Smith, C.; Blankenberg, F.G. Structural requirements for in vivo detection of cell death with 99mTc-annexin V. J. Nucl. Med. 2005, 46, 807.
40. Jin, M.; Smith, C.; Hsieh, H.Y.; Gibson, D.F.; Tait, J.F. Essential role of B-helix calcium binding sites in annexin V-membrane binding. J. Biol. Chem., 2004, 279, 40351.
41. Mukherjee, A.; Kothari, K.; Tóth, G.; Szemenyei, E.; Sarma, H.D.; Környei, J.; Venkatesh, M. 99mTc-labeled annexin V fragments: a potential SPECT radiopharmaceutical for imaging cell death. Nucl. Med. Biol., 2006, 33, 635.
42. Tait, J.F.; Smith, C.; Levashova, Z.; Patel, B.; Blankenberg, F.G.; Vanderheyden, J.L. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J. Nucl. Med., 2006, 47, 1546.
43. Lahorte, C.M.M.; Vanderheyden, J-L.; Steinmetz, N.; Van de Wiele, C.; Dierckx, R.A.; Slegers, G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 887.
44. Laufer, E.M.; Reutelingsperger, C.P.; Narula, J.; Hofstra, L. Annexin A5: an imaging biomarker of cardiovascular risk. Basic Res. Cardiol., 2008, 103, 95.
45. Strauss, H.W.; Blankenberg, F.; Vanderheyden, J.L.; Tait, J. Translational imaging: imaging of apoptosis. Handb. Exp. Pharmacol., 2008, 185, 259.
46. Blankenberg, F.G. In vivo detection of apoptosis. J. Nucl. Med., 2008, 49, 81S.
47. Lahorte, C.M.; van de Wiele, C.; Bacher, K.; van den Bossche, B.; Thierens, H.; van Belle, S.; Slegers, G.; Dierckx, R.A. Biodistribution and dosimetry study of 123I-rh-annexin V in mice and humans. Nucl. Med. Commun., 2003, 24, 871.
48. Quinti, L.; Weissleder, R.; Tung, C.H. A fluorescent nanosensor for apoptotic cells. Nano. Lett., 2006, 6, 488.
49. Keen, H.G.; Dekker, B.A.; Disley, L.; Hastings, D.; Lyons, S.; Reader, A.J.; Ottewell, P.; Watson, A.; Zweit, J. Imaging apoptosis in vivo using 124I-annexin V and PET. Nucl. Med. Biol., 2005, 32, 395.
50. Cauchon, N.; Langlois, R.; Rousseau, J.A.; Tessier, G.; Cadorette, J.; Lecomte, R.; Hunting, D.J.; Pavan, R.A.; Zeisler, S.K.; van Lier, J.E. PET imaging of apoptosis with 64Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur. J. Nucl. Med. Mol. Imaging., 2007, 34, 247.
51. Grierson, J.R.; Yagle, K.J.; Eary, J.F.; Tait, J.F.; Gibson, D.F.; Lewellen, B.; Link, J.M.; Krohn, K.A. Production of [F-18]fluoroannexin for imaging apoptosis with PET. Bioconjug. Chem., 2004, 15, 373.
52. Murakami, Y.; Takamatsu, H.; Taki, J.; Tatsumi, M.; Noda, A.; Ichise, R.; Tait, J.F.; Nishimura, S. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 469.
53. Lahorte, C.M.M.; Vanderheyden, J-L.; Steinmetz, N.; Van de Wiele, C.; Dierckx, R.A.; Slegers, G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31, 887.
54. van Tilborg, G.A.; Mulder, W.J.; Deckers, N.; Storm, G.; Reutelingsperger, C.P.; Strijkers, G.J.; Nicolay, K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem., 2006, 17, 741.
55. Dekker, B.; Keen, H.; Shaw, D; Disley, L.; Hastings, D; Hadfield, J.; Reader, A.; Allan, D.; Julyan, P.; Watson, A.; Zweit, J. Functional comparison of annexin V analogues labeled indirectly and directly with iodine-124. Nucl. Med. Biol., 2005, 32, 403.
56. Blankenberg, F. To scan or not to scan, it is a question of timing: technetium-99m-annexin V radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin. Cancer. Res., 2002, 8, 2757.
57. Vermeersch, H.; Ham, H.; Rottey, S.; Lahorte, C.; Corsetti, F.; Dierckx, R.; Steinmetz, N.; Van de Wiele, C. Intraobserver, interobserver, and day-to-day reproducibility of quantitative 99mTc-HYNIC annexin-V imaging in head and neck carcinoma. Cancer. Biother. Radiopharm., 2004, 19, 205.
58. Kartachova, M.; Haas, R.L.; Olmos, R.A.; Hoebers, F.J.; van Zandwijk, N.; Verheij, M. In vivo imaging of apoptosis by 99mTc-Annexin V scintigraphy: visual analysis in relation to treatment response. Radiother. Oncol., 2004, 72, 333.
59. Gardzinski, P.; Lee, D.W.; Fei, G.H.; Hui, K.; Huang, G.J.; Sun, H.S.; Feng, Z.P. The role of synaptotagmin I C2A calcium-binding domain in synaptic vesicle clustering during synapse formation. J. Physiol., 2007, 581, 75.
60. Zhang, X.; Rizo, J.; Südhof, T.C. Mechanism of phospholipid binding by the C2A-domain of synaptotagmin I. Biochemistry, 1998, 37, 12395.
61. Sutton, R.B.; Davletov, B.A.; Berghuis, A.M.; Südhof, T.C.; Sprang, S.R. Structure of the first C2 domain of synaptotagmin I: a novel Ca2+/phospholipid-binding fold. Cell, 1995, 80, 929.
62. Davletov, B.A.; Südhof, T.C. A single C2 domain from synaptotagmin I is sufficient for high affinity Ca2+/phospholipid binding. J. Biol. Chem., 1993, 268, 26386.
63. Jung, H.I.; Kettunen, M.I.; Davletov, B.; Brindle, K.M. Detection of apoptosis using the C2A domain of synaptotagmin I. Bioconjug. Chem., 2004, 15, 983.
64. Zhao, M.; Beauregard, D.A.; Loizou, L.; Davletov, B.; Brindle, K.M. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med., 2001, 7, 1241.
65. Zhao, M.; Zhu, X.; Ji, S.; Zhou, J.; Ozker, K.S.; Fang, W.; Molthen, R.C.; Hellman, R.S. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J. Nucl. Med., 2006, 47, 1367.
66. Liu, Z.; Zhao, M.; Zhu, X.; Furenlid, L.R.; Chen, Y.C.; Barrett, H.H. In vivo dynamic imaging of myocardial cell death using 99mTc-labeled C2A domain of synaptotagmin I in a rat model of ischemia and reperfusion. Nucl. Med. Biol., 2007, 34, 907.
67. Fang, W.; Wang, F.; Ji, S.; Zhu, X.; Meier, H.T.; Hellman, R.S.; Brindle, K.M.; Davletov, B.; Zhao, M. SPECT imaging of myocardial infarction using 99mTc-labeled C2A domain of synaptotagmin I in a porcine ischemia-reperfusion model. Nucl. Med. Biol., 2007, 34, 917.
68. Krishnan, A.S.; Neves, A.A.; de Backer, M.M.; Hu, D.E.; Davletov, B.; Kettunen, M.I.; Brindle, K.M. Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology, 2008, 246, 854.
69. Wang, F.; Fang, W.; Zhao, M.; Wang, Z.; Ji, S; Li, Y.; Zheng, Y. Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study. Nucl. Med. Biol., 2008, 35, 359.
70. Navarro, J.; Chabot, J.; Sherrill, K.; Aneja, R.; Zahler, S.A.; Racker, E. Interaction of duramycin with artificial and natural membranes. Biochemistry, 1985, 24, 4645.
71. Machaidze, G.; Ziegler, A.; Seelig, J. Specific binding of Ro 09-0198 (cinnamycin) to phosphatidylethanolamine: a thermodynamic analysis. Biochemistry, 2002, 41, 1965.
72. Hayashi, F.; Nagashima, K.; Terui, Y.; Kawamura, Y.; Matsumoto, K.; Itazaki, H. The structure of PA48009: the revised structure of duramycin. J. Antibiot., 1990, 43, 1421.
73. Zimmermann, N.; Freund, S.; Fredenhagen, A.; Jung, G. Solution structures of the lantibiotics duramycin B and C. Eur. J. Biochem., 1993, 216, 419.
74. Kaletta, C.; Entian, K.D.; Jung G. Prepeptide sequence of cinnamycin (Ro 09-0198): the first structural gene of a duramycin-type lantibiotic. Eur. J. Biochem., 1991, 199,411.
75. Zhao, M.; Li, Z.; Bugenhagen, S. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J. Nucl. Med., 2008, 49, 1345.
76. Aoki, Y.; Uenaka, T.; Aoki, J.; Umeda, M.; Inoue, K. A novel peptide probe for studying the transbilayer movement of phosphatidylethanolamine. J. Biochem., 1994, 116, 291.
77. Huang, M.; Rigby, A.C.; Morelli, X.; Grant, M.A.; Huang, G.; Furie, B.; Seaton, B.; Furie, B.C. Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins. Nat. Struct. Biol., 2003, 10, 751.
78. Cohen, A.; Shirvan, A.; Levin, G.; Grimberg, H.; Reshef, A.; Ziv, I. From the Gla domain to a novel small-molecule detector of apoptosis. Cell Res., 2009, 19, 625.
79. Grimberg, H,; Levin, G.; Shirvan, A.; Cohen, A.; Yogev-Falach, M.; Reshef, A.; Ziv, I. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis, 2009, 14, 257.
80. Aloya, R.; Shirvan, A.; Grimberg, H.; Reshef, A.; Levin, G.; Kidron, D.; Cohen, A.; Ziv, I. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis, 2006, 11, 2089.
81. Zhou, D.; Chu, W.; Chen, D.L.; Wang, Q.; Reichert, D.E.; Rothfuss, J.; D'Avignon, A.; Welch, M.J.; Mach, R.H. [18F]- and [11C]-labeled N-benzyl-isatin sulfonamide analogues as PET tracers for apoptosis: synthesis, radiolabeling mechanism, and in vivo imaging study of apoptosis in Fas-treated mice using [11C]WC-98. Org. Biomol. Chem., 2009, 7, 1337.
82. Podichetty, A.K.; Wagner, S.; Schröer, S.; Faust, A.; Schäfers, M.; Schober, O.; Kopka, K.; Haufe, G. Fluorinated isatin derivatives. Part 2. New N-substituted 5-pyrrolidinylsulfonyl isatins as potential tools for molecular imaging of caspases in apoptosis. J. Med. Chem., 2009, 52, 3484.
83. Maxwell, D.; Chang, Q.; Zhang, X.; Barnett, E.M.; Piwnica-Worms, D. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent Peptide for apoptosis imaging. Bioconjug. Chem., 2009, 20, 702.
84. Gammon, S.T.; Villalobos, V.M.; Roshal, M.; Samrakandi, M.; Piwnica-Worms, D. Rational design of novel red-shifted BRET pairs: Platforms for real-time single-chain protease biosensors. Biotechnol. Prog., 2009, 25, 559.
85. Li, Y.; Xing, D.; Chen, Q. Dynamic monitoring of apoptosis in chemotherapies with multiple fluorescence reporters. Dynamic monitoring of apoptosis in chemotherapies with multiple fluorescence reporters. Mol. Imaging Biol., 2009, 11, 213.
86. Smith, G.; Glaser, M.; Perumal, M.; Nguyen, Q.D.; Shan, B.; Arstad, E.; Aboagye, E.O. Design, synthesis, and biological characterization of a caspase 3/7 selective isatin labeled with 2-[18F]fluoroethylazide. J. Med. Chem., 2008, 51, 8057.
87. Messerli, S.M.; Prabhakar, S.; Tang, Y.; Shah, K.; Cortes, M.L.; Murthy, V.; Weissleder, R.; Breakefield, X.O.; Tung, C.H. A novel method for imaging apoptosis using a caspase-1 near-infrared fluorescent probe. Neoplasia, 2004, 6, 95.
88. Harpur, A.G.; Wouters, F.S.; Bastiaens, P.I. Imaging FRET between spectrally similar GFP molecules in single cells. Nat. Biotechnol., 2001, 19, 167.
89. Eckelman, W.C.; Kilbourn, M.R.; Mathis, C.A. Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems! Nucl. Med. Biol., 2009, 36, 235.
90. Mintun, M.A.; Raichle, M.E.; Kilbourn, M.R.; Wooten, G.F.; Welch, M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol., 1984, 15, 217.
91. Eckelman, W.C.; Reba, R.C.; Kelloff, G.J. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov. Today, 2008, 13, 748.
92. Slifstein, M.; Laruelle, M. Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers. Nucl. Med. Biol., 2001, 28, 595.
93. Ichise, M.; Meyer, J.H.; Yonekura, Y. An introduction to PET and SPECT neuroreceptor quantification models. J. Nucl. Med., 2001, 42, 755.
94. Audi, S.; Poellmann, M.; Zhu, X.; Li, Z.; Zhao, M. Quantitative analysis of [99mTc]C2A-GST distribution in the area at risk after myocardial ischemia and reperfusion using a compartmental model. Nucl. Med. Biol., 2007, 34, 897.
95. Blankenberg, F.G.; Storrs, R.W.; Naumovski, L.; Goralski, T.; Spielman, D. Detection of apoptotic cell death by proton nuclear magnetic resonance spectroscopy. Blood, 1996, 87, 1951.
96. Hakumäki, J.M.; Poptani, H.; Sandmair, A.M.; Ylä-Herttuala, S.; Kauppinen, R.A. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat. Med., 1999, 5, 1323.
97. Hakumäki, J.M.; Poptani, H.; Puumalainen, A.M.; Loimas, S.; Paljärvi, L.A.; Ylä-Herttuala, S.; Kauppinen, R.A. Quantitative 1H nuclear magnetic resonance diffusion spectroscopy of BT4C rat glioma during thymidine kinase-mediated gene therapy in vivo: identification of apoptotic response. Cancer Res., 1998, 58, 3791.
98. Liimatainen, T.; Hakumäki, J.M.; Kauppinen, R.A.; Ala-Korpela, M. Monitoring of gliomas in vivo by diffusion MRI and (1)H MRS during gene therapy-induced apoptosis: interrelationships between water diffusion and mobile lipids. NMR Biomed., 2009, 22, 272.
99. Czarnota, G.J.; Kolios, M.; Vaziri, H.; Benchimol, S.; Ottensmeyer, F.P.; Hunt, J.W. Ultrasound biomicroscopy of living, dead, and apoptotic cells. Ultrasound Med. Biol., 1997, 23, 961.
100. Czarnota, G.J.; Kolios, M.C.; Abraham, J.; Portnoy, M.; Ottensmeyer, F.P.; Hunt, J.W.; Sherar, M.D. Ultrasound imaging of apoptosis: high resolution non-invasive monitoring of programmed cell death in vitro, in situ, and in vivo. Br. J. Cancer, 1999, 81, 520.
101. Kolios, M.C.; Czarnota, G.J.; Ottensmeyer, F.P.; Hunt, J.W.; Sherar, M.D.; Hunt, J.W. Ultrasonic spectral parameter characterization of apoptosis. Ultrasound Med. Biol., 2002, 28, 589.